Individual isotoxic radiation dose escalation based on V20 and advanced technologies benefits unresectable stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy: long term follow-up-Reference-Cited by-同舟云学术

Individual isotoxic radiation dose escalation based on V20 and advanced technologies benefits unresectable stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy: long term follow-up

Published:2017-03-16 Issue:31 Volume:8 Page:51848-51858
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Liu Ming¹²,Wang Zhongtang²,Zhou Tao²,Zhou Antang³,Zhao Qian²,Li Hongsheng²,Sun Hongfu²,Huang Wei²,Li BaoSheng²⁴

Affiliation:

1. School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China

2. Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China

3. Department of General Surgery, Yanggu People’s Hospital, Liaocheng, Shandong, P.R. China

4. Engineering Research Center for Medical Imaging and Radiation Therapy of Shandong Province, Jinan, Shandong, P.R. China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of cone beam computed tomography based online adaptive radiotherapy: current trend and future direction;Radiation Oncology;2023-09-02

2. Clinical management of stage III non‐small cell lung cancer in India: An expert consensus statement;Asia-Pacific Journal of Clinical Oncology;2023-02-23

3. Integrated MRI-guided radiotherapy — opportunities and challenges;Nature Reviews Clinical Oncology;2022-04-19

4. Adaptive Radiation Therapy (ART) Strategies and Technical Considerations: A State of the ART Review From NRG Oncology;International Journal of Radiation Oncology*Biology*Physics;2021-03

5. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma;Therapeutic Advances in Medical Oncology;2021-01